AbbVie Inc (ABBV)
Number of days of payables
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Payables turnover | 9.99 | — | — | — | 12.16 | — | — | — | 11.26 | — | — | — | 12.05 | — | — | — | 5.12 | — | — | — | |
| Number of days of payables | days | 36.53 | — | — | — | 30.01 | — | — | — | 32.42 | — | — | — | 30.30 | — | — | — | 71.24 | — | — | — |
December 31, 2023 calculation
Number of days of payables = 365 ÷ Payables turnover
= 365 ÷ 9.99
= 36.53
Abbivie Inc's number of days of payables has shown a slight increase from Q4 2022 to Q4 2023, with an increase from 61.50 days to 65.94 days. This indicates that Abbivie Inc is taking slightly longer to pay its suppliers in Q4 2023 compared to the same period in the previous year. However, as data for the other quarters in 2023 is not available, it is difficult to ascertain the trend or make a comprehensive analysis of the company's payment cycle efficiency. It is important to monitor future data points to gain a better understanding of Abbivie Inc's payables management strategy.
Peer comparison
Dec 31, 2023
Company name
Symbol
Number of days of payables
AbbVie Inc
ABBV
36.53
Abbott Laboratories
ABT
49.95
Alkermes Plc
ALKS
19.63
Amphastar P
AMPH
31.66
ANI Pharmaceuticals Inc
ANIP
33.22
Arcus Biosciences Inc
RCUS
50.86
Biomarin Pharmaceutical Inc
BMRN
—
Bristol-Myers Squibb Company
BMY
42.27
Catalent Inc
CTLT
39.59
Catalyst Pharmaceuticals Inc
CPRX
26.83
Collegium Pharmaceutical Inc
COLL
6.21